ArthralgiaPhase 3NCT01385137
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
A Phase 3 study testing omega-3 fatty acid in people with Arthralgia and Breast Cancer, run by SWOG Cancer Research Network at 292 sites in United States.
Trial summary
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer. PURPOSE: This randomized phase III trial is studying omega-3 fatty acid supplements in treating muscle and bone pain and stiffness in patients… Read more about this study
- Who is it for?
- Ages 18 to 120 years, women only
- Conditions the study is for
- Arthralgia, Breast Cancer, Pain
- What is being tested?
- omega-3 fatty acid
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 262 participants
- Where
- 292 sitesUnited States
- Study dates
- Feb 2012to Mar 2014
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- Women only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed primary invasive adenocarcinoma of the breast
- Stage I, II, or IIIA disease
- No metastatic disease
- Must have undergone modified radical mastectomy or breast-sparing surgery and recovered
- Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+)
- Currently taking a third-generation aromatase inhibitor (AI) [e.g., anastrozole (Arimidex®), letrozole (Femara®), or exemestane (Aromasin®)] for ≥ 90 days prior to registration with plans to continue for ≥ 180 days after registration
- Must have completed the S092 Brief Pain Inventory (BPI)-Short Form within the past 14 days, and must have a worst pain/stiffness of ≥ 5 on the BPI (item #2) that has started or increased with AI therapy
PATIENT CHARACTERISTICS:
- Postmenopausal
- Zubrod performance status 0-2
- Willing to submit blood for serum-free estradiol, total estradiol, serum inflammatory markers (IL6, TNF-α, CRP), DHA and EPA, lipid profile (LDL, HDL, triglycerides), and DNA analysis (CYP19A1)
- Able to complete study questionnaires in English
- At least 5 years since other malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast or adequately treated stage I or II cancer from which the patient is currently in complete remission
- Patients must not have a known allergy to soy, given that the placebo is suspended in soybean oil
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 3 months since prior omega-3 fatty acid supplements and must agree to refrain from omega-3-fatty acid supplements from sources outside of this study
- More than 28 days since prior investigational agents
- No other medical therapy, alternative therapy, or physical therapy for joint pain/stiffness within the past 30 days
- Patients must not be on anticoagulation medication (i.e., heparin/warfarin) because of increased risk of bleeding within 28 days prior to registration
- Patients must not have a history of bone fracture or surgery of the afflicted knees and/or hands within 6 months prior to registration
- Patients must not be on narcotics within 14 days of registration
- Patients may have received corticosteroid treatment; however, the following criteria apply:
- Patients must not have received oral or intramuscular corticosteroids within the 28 days prior to registration
- Patients must not have received intra-articular steroids to the study, or any other, joint within 28 days prior to registration
- Patients must not have received topical analgesics (e.g., capsaicin preparations) to the study joint or any other analgesics (e.g., opiates, tramadol; with the exception of nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen) within 14 days prior to registration
Trial locations and contacts
292 sites in 1 country.
292 sites in 1 country
United States292 sites
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Lovelace Medical Center - Downtown
Albuquerque, New Mexico, 87102
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
CHRISTUS Cabrini Cancer Center
Alexandria, Louisiana, 71301
American Fork Hospital
American Fork, Utah, 84003
Island Hospital Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Kaiser Permanente Medical Center - Anaheim/Orange County
Anaheim, California, 92807
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0942
Kaiser Permanente - Deer Valley
Antioch, California, 94531
Randolph Hospital
Asheboro, North Carolina, 27203-5400
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Kaiser Permanente Medical Center - Baldwin Park
Baldwin Park, California, 91706
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
Baltimore, Maryland, 21215
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
Bay Regional Medical Center
Bay City, Michigan, 48708
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Kaiser Permanente Medical Center - Bellflower
Bellflower, California, 90706
St. Joseph Cancer Center
Bellingham, Washington, 98225
St. Charles Medical Center - Bend
Bend, Oregon, 97701
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, 83712
Central Care Cancer Center at Carrie J. Babb Cancer Center
Bolivar, Missouri, 65613
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Highline Medical Center Cancer Center
Burien, Washington, 98166
Peninsula Medical Center
Burlingame, California, 94010
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts, 01805
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Rocky Mountain Oncology
Casper, Wyoming, 82609
Sandra L. Maxwell Cancer Center
Cedar City, Utah, 84720
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Baylor University Medical Center - Dallas
Dallas, Texas, 75246
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Kaiser Permanente - Denver
Denver, Colorado, 80205
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Falck Cancer Center at Arnot Ogden Medical Center
Elmira, New York, 14905
Providence Regional Cancer Partnership
Everett, Washington, 98201
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
McLaren Cancer Institute
Flint, Michigan, 48532
Singh and Arora Hematology Oncology, PC
Flint, Michigan, 48532
McLeod Regional Medical Center
Florence, South Carolina, 29501
Kaiser Permanente Medical Center - Fontana
Fontana, California, 92335
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Broward General Medical Center Cancer Center
Fort Lauderdale, Florida, 33316
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Kaiser Permanente - Fremont
Fremont, California, 94538
Kaiser Permanente Fresno Medical Center
Fresno, California, 93720
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, 83619
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
CaroMont Cancer Center at Gaston Memorial Hospital
Gastonia, North Carolina, 28053
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27403-1198
Wayne Hospital
Greenville, Ohio, 45331
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Grove Commons
Greenville, South Carolina, 29605
CCOP - Greenville
Greenville, South Carolina, 29615
Self Regional Cancer Center at Self Regional Medical Center
Greenwood, South Carolina, 29646
Cancer Centers of the Carolinas - Greer Medical Oncology
Greer, South Carolina, 29650
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Kaiser Permanente Medical Center - Harbor City
Harbor City, California, 90710
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Kaiser Permanente - Moanalua Medical Center and Clinic
Honolulu, Hawaii, 96819
Methodist Hospital
Houston, Texas, 77030
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Kaiser Permanente - Irvine
Irvine, California, 92618
Baylor Medical Center at Irving
Irving, Texas, 75061
Swedish Medical Center - Issaquah Campus
Issaquah, Washington, 98029
Foote Memorial Hospital
Jackson, Michigan, 49201
University of Mississippi Cancer Clinic
Jackson, Mississippi, 39216
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology Oncology Associates, Incorporated
Kansas City, Missouri, 64118
Research Medical Center
Kansas City, Missouri, 64132
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Columbia Basin Hematology
Kennewick, Washington, 99336
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Cascade Cancer Center at Evergreen Hospital Medical Center
Kirkland, Washington, 98033
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
Fairfield Medical Center
Lancaster, Ohio, 43130
Carolina Blood and Cancer Care Associates, PA
Lancaster, South Carolina, 29720
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Great Lakes Cancer Institute - Lapeer Campus
Lapeer, Michigan, 48446
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
St. Joseph Regional Medical Center
Lewiston, Idaho, 83501
Central Baptist Hospital
Lexington, Kentucky, 40503-9985
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67901
Parvin Radiation Oncology
Liberty, Missouri, 64068
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Logan Regional Hospital
Logan, Utah, 84321
Kaiser Permanente Medical Center - Los Angeles
Los Angeles, California, 90027
Kaiser Foundation Hospital - West Los Angeles
Los Angeles, California, 90034
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90089-9181
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California, 95901
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Mercy Cancer Center at Mercy Medical Center
Merced, California, 95340
Mountain States Tumor Institute - Meridian
Meridian, Idaho, 83642
Tucker Center for Cancer Care at Orange Regional Medical Center
Middletown, New York, 10940-4199
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Winthrop University Hospital
Mineola, New York, 11501
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Providence Cancer Center at Providence Hospital
Mobile, Alabama, 36608
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Clemens Regional Medical Center
Mount Clemens, Michigan, 48043
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98274
El Camino Hospital Cancer Center
Mountain View, California, 94040
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
Murray, Utah, 84157
Mercy General Health Partners
Muskegon, Michigan, 49444
Saint Luke's Mountain States Tumor Institute
Nampa, Idaho, 83686
Edward Hospital Cancer Center
Naperville, Illinois, 60540
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, 10032
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Sutter Health - Western Division Cancer Research Group
Novato, California, 94945
Highland General Hospital
Oakland, California, 94602
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Kaiser Permanente Medical Center - Oakland
Oakland, California, 94611
Epic Care - Oakland
Oakland, California, 94612
Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
Ogden, Utah, 84403
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 98506-5166
Willamette Falls Hospital
Oregon City, Oregon, 97045
Menorah Medical Center
Overland Park, Kansas, 66209
Saint Luke's Hospital - South
Overland Park, Kansas, 66213
Kaiser Permanente Medical Group
Panorama City, California, 91402
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Regional Cancer Center at Singing River Hospital
Pascagoula, Mississippi, 39581
Northern Michigan Hospital
Petoskey, Michigan, 49770
Valley Medical Oncology Consultants - Pleasanton
Pleasanton, California, 94588
St. Joseph Mercy Oakland
Pontiac, Michigan, 48341-2985
Mercy Regional Cancer Center at Mercy Hospital
Port Huron, Michigan, 48060
Legacy Good Samaritan Hospital & Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Legacy Emanuel Hospital and Health Center and Children's Hospital
Portland, Oregon, 97227
Southern Ohio Medical Center Cancer Center
Portsmouth, Ohio, 45662
Harrison Poulsbo Hematology and Onocology
Poulsbo, Washington, 98370
CCOP - Kansas City
Prairie Village, Kansas, 66208
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84604
Good Samaritan Cancer Center
Puyallup, Washington, 98372
Kaiser Permanente Medical Center - Redwood City
Redwood City, California, 94063
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Kaiser Permanente Medical Center - Richmond
Richmond, California, 94801
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Kaiser Permanente Medical Center - Riverside
Riverside, California, 92505
Highland Hospital of Rochester
Rochester, New York, 14620
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Carolina Blood and Cancer Care
Rock Hill, South Carolina, 29732
Highlands Oncology Group - Springdale
Rogers, Arkansas, 72758
Phelps County Regional Medical Center
Rolla, Missouri, 65401
Kaiser Permanente Medical Center - Roseville
Roseville, California, 95661
Sutter Cancer Center at Roseville Medical Center
Roseville, California, 95661
Sutter Cancer Center
Sacramento, California, 95816
University of California Davis Cancer Center
Sacramento, California, 95817
South Sacramento Kaiser-Permanente Medical Center
Sacramento, California, 95823
Kaiser Permanente Medical Center - Sacramento
Sacramento, California, 95825
Seton Cancer Institute at Saint Mary's - Saginaw
Saginaw, Michigan, 48601
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Salem Hospital Regional Cancer Care Services
Salem, Oregon, 97309-5014
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67401
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112
LDS Hospital
Salt Lake City, Utah, 84143
Kaiser Permanente Medical Office -Vandever Medical Office
San Diego, California, 92108
Kaiser Permanente Medical Center - Kaiser Foundation Hospital - San Diego
San Diego, California, 92120
Kaiser Permanente Medical Center - San Francisco Geary Campus
San Francisco, California, 94115
California Pacific Medical Center - California Campus
San Francisco, California, 94118
Kaiser Permanente Medical Center - Santa Teresa
San Jose, California, 95119
Kaiser Permanente Health Care
San Marcos, California, 92078
Doctors Medical Center - San Pablo Campus
San Pablo, California, 94806
Kaiser Foundation Hospital - San Rafael
San Rafael, California, 94903
Kaiser Permanente Medical Center - Santa Clara Kiely Campus
Santa Clara, California, 95051
Kaiser Permanente Medical Center - Santa Rosa
Santa Rosa, California, 95403
Sutter Pacific Medical Foundation
Santa Rosa, California, 95403
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
Savannah, Georgia, 31403-3089
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
Harborview Medical Center
Seattle, Washington, 98104
Minor and James Medical, PLLC
Seattle, Washington, 98104
Pacific Medical Center
Seattle, Washington, 98104
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
Group Health Central Hospital
Seattle, Washington, 98112
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98122-4307
Polyclinic First Hill
Seattle, Washington, 98122
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195
North Puget Oncology at United General Hospital
Sedro-Woolley, Washington, 98284
Cancer Centers of the Carolinas - Seneca
Seneca, South Carolina, 29672
Highland Clinic
Shreveport, Louisiana, 71105
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Shreveport, Louisiana, 71130-3932
Kaiser Permanente Medical Center - South San Francisco
South San Francisco, California, 94080
Providence Cancer Institute at Providence Hospital - Southfield Campus
Southfield, Michigan, 48075
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
Cancer Centers of the Carolinas - Spartanburg
Spartanburg, South Carolina, 29307
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Evergreen Hematology and Oncology, PS
Spokane, Washington, 99218
Regional Cancer Center at Memorial Medical Center
Springfield, Illinois, 62781-0001
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Midwest Hematology Oncology Group, Incorporated
St Louis, Missouri, 63109
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Dixie Regional Medical Center - East Campus
St. George, Utah, 84770
Iredell Memorial Hospital
Statesville, North Carolina, 28677
Kaiser Permanente Medical Facility - Stockton
Stockton, California, 95210
Franciscan Cancer Center at St. Joseph Medical Center
Tacoma, Washington, 98405-3004
Allenmore Hospital
Tacoma, Washington, 98405
CCOP - Northwest
Tacoma, Washington, 98405
MultiCare Regional Cancer Center at Tacoma General Hospital
Tacoma, Washington, 98405
St. Clare Hospital
Tacoma, Washington, 98499
Cotton-O'Neil Cancer Center
Topeka, Kansas, 66606
Munson Medical Center
Traverse City, Michigan, 49684
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
Tahoe Forest Cancer Center
Truckee, California, 96161
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Mountain States Tumor Institute at St. Luke's
Twin Falls, Idaho, 83301
Kaiser Permanente Medical Center - Vacaville
Vacaville, California, 95688
Kaiser Permanente Medical Center - Vallejo
Vallejo, California, 94589
Sutter Solano Medical Center
Vallejo, California, 94589
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98664
Legacy Salmon Creek Medical Center
Vancouver, Washington, 98686
Kaiser Permanente Medical Center - Walnut Creek
Walnut Creek, California, 94596
St. John Macomb Hospital
Warren, Michigan, 48093
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Wenatchee Valley Medical Center
Wenatchee, Washington, 98801-2028
Mount Carmel St. Ann's Cancer Center
Westerville, Ohio, 43081
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Kaiser Permanente Medical Cener - Woodland Hills
Woodland Hills, California, 91367
United States Air Force Medical Center - Wright-Patterson
Wright-Patterson AFB, Ohio, 45433-5529
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
PURPOSE: This randomized phase III trial is studying omega-3 fatty acid supplements in treating muscle and bone pain and stiffness in patients with stage I, stage II, or stage III breast cancer receiving hormone therapy.
Read the detailed description
OBJECTIVES:
Primary
- To assess whether omega-3-fatty acid as compared to placebo causes a reduction in worst joint pain and/or stiffness at 12 weeks, as measured by the modified Brief Pain Inventory (BPI), in women with early-stage breast cancer and aromatase inhibitor (AI)-associated arthralgia.
Secondary
- To assess the proportion of patients who report improved versus deteriorated joint pain with omega-3-fatty acid versus placebo.
- To assess the proportion of patients who report improved versus deteriorated joint stiffness with omega-3-fatty acid versus placebo.
- To assess whether patients receiving omega-3-fatty acid compared to placebo have decreased analgesic use and increased AI adherence.
- To assess whether patients receiving omega-3-fatty acid compared to placebo have improved functioning, pain, and stiffness in the knees/hips (as measured by the Western Ontario and McMaster Universities Osteoarthritis, WOMAC) score.
- To assess whether patients receiving omega-3-fatty acid have improved functioning, pain, and stiffness in the hands (as measured by the Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands, M-SACRAH).
- To assess whether patients receiving omega-3-fatty acid compared to placebo have improved functional quality of life as measured by the Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) Trial Outcome Index (TOI).
- To assess whether patients receiving omega-3-fatty acid report changes for the better versus worse compared to placebo as measured by the Global Rating of Change Scale.
- To identify minimally important change in the WOMAC, M-SACRAH, and the FACT-ES Trial Outcome Index (TOI) using "a little better" or "a little worse" responses on the patient-reported global rating of change in joint pain and joint stiffness.
- To assess whether patients receiving omega-3-fatty acid compared to placebo have an improved lipid profile as measured by triglycerides, HDL, and LDL.
- To assess the toxicity of omega-3-fatty acid compared to placebo in this setting.
- To assess whether there is a difference in serum-free and total estradiol levels before and after treatment with omega-3-fatty acid compared to placebo.
- To explore whether CYP19A1 genotype correlates with severity of joint symptoms or predicts response to omega-3-fatty acid. (exploratory)
- To explore changes in hormonal and inflammatory serum biomarkers, such as IL6, TNF-α, and CRP.
- To assess whether there is a relationship between change in serum docosahexaenoic acid (DHA) and EPA and resolution of joint symptoms.
- To establish a cohort of patients (placebo group) to better characterize the natural history of the syndrome.
OUTLINE: This is a multicenter study. Patients are stratified according to prior osteoarthritis (yes vs no) and prior taxane use (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample collection at baseline and at 12 and 24 weeks for biomarker and DNA analysis.
Patients complete the Brief Pain Inventory Short Form (BPI-SF), the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index, the Modified-Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH), the FACT-ES Trial Outcome Index, and the Omega-3-fatty acid Dietary Intake questionnaires at baseline and at 6, 12, and 24 weeks.
- Conditions
- Arthralgia, Breast Cancer, Pain
- Being tested
- omega-3 fatty acid, placebo
- Keywords
- estrogen receptor-positive breast cancer, progesterone receptor-positive breast cancer, stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, pain, arthralgia
- Medical subject headings
- Arthralgia, Breast Neoplasms, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
omega-3 fatty acidDietary supplement
Given orally
placeboOther
Given orally
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Experimental | Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity. Receives: Dietary Supplement: omega-3 fatty acid |
| Arm II | Placebo comparator | Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity. Receives: Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score
Linear regression model-adjusted week 12 mean score by treatment group.
Purpose: To assess the severity of pain Population: Patients with pain from chronic diseases or conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain Responsiveness: Responds to both behavioral and pharmacological pain interventions Method: Self-report or interview Scoring: Higher scores indicate more pain Range: 0-10
Measured: 12 weeks post-registration
Secondary outcomes (4)
Number of Patients With Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Measured: Up to 25 weeks
Week 12 Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score
Linear regression model-adjusted week 12 mean score by treatment group The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Higher scores indicate higher symptom burden.
Measured: 12 weeks post-registration
Week 12 Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH) Score
Linear regression model-adjusted week 12 mean score by treatment group. Higher scores represent higher symptom burden. Range is 0 to 100.
Measured: 12 weeks post-registration
Week 12 Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Score
FACT-ES measures physical, social and family, emotional, and functional well-being and endocrine symptoms. The FACT scaleshave five response levels ("not at all" to "very much"), where higher scores reflect better well-being and fewer symptoms. This scale provided a measure of the broader impact of join pain and stiffness symptoms. Score range is 0 to 220.
Measured: 12 weeks post-registration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2011 (estimated)
- Study startFeb 2012
- Primary completionDec 2013
- Study completionMar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ArthralgiaStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 262 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Dawn Hershman, MD, Study chair, Herbert Irving Comprehensive Cancer CenterLaurence H. Baker, DO, FACOI, Principal investigator, University of Michigan Rogel Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01385137
- Sponsor's protocol ID
- S0927
- Other IDs
- S0927, U10CA037429
- Status last verified
- Feb 2017
- First submitted
- 28 Jun 2011
- Last updated
- 7 Apr 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. J Clin Oncol. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4.
PubMed 25940724
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
- ClinicalTrials.gov ID
- NCT01385137
- Acronym / sponsor ID
- S0927
- Conditions
- Arthralgia, Breast Cancer, Pain
- Keywords
- estrogen receptor-positive breast cancer, progesterone receptor-positive breast cancer, stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, pain, arthralgia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 262 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Feb 2012
- Primary completion
- Dec 2013 (actual)
- Study completion
- Mar 2014 (actual)
- First posted
- 29 Jun 2011 (estimated)
- Results
- Posted 7 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
PURPOSE: This randomized phase III trial is studying omega-3 fatty acid supplements in treating muscle and bone pain and stiffness in patients with stage I, stage II, or stage III breast cancer receiving hormone therapy.
Detailed description
OBJECTIVES:
Primary
- To assess whether omega-3-fatty acid as compared to placebo causes a reduction in worst joint pain and/or stiffness at 12 weeks, as measured by the modified Brief Pain Inventory (BPI), in women with early-stage breast cancer and aromatase inhibitor (AI)-associated arthralgia.
Secondary
- To assess the proportion of patients who report improved versus deteriorated joint pain with omega-3-fatty acid versus placebo.
- To assess the proportion of patients who report improved versus deteriorated joint stiffness with omega-3-fatty acid versus placebo.
- To assess whether patients receiving omega-3-fatty acid compared to placebo have decreased analgesic use and increased AI adherence.
- To assess whether patients receiving omega-3-fatty acid compared to placebo have improved functioning, pain, and stiffness in the knees/hips (as measured by the Western Ontario and McMaster Universities Osteoarthritis, WOMAC) score.
- To assess whether patients receiving omega-3-fatty acid have improved functioning, pain, and stiffness in the hands (as measured by the Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands, M-SACRAH).
- To assess whether patients receiving omega-3-fatty acid compared to placebo have improved functional quality of life as measured by the Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) Trial Outcome Index (TOI).
- To assess whether patients receiving omega-3-fatty acid report changes for the better versus worse compared to placebo as measured by the Global Rating of Change Scale.
- To identify minimally important change in the WOMAC, M-SACRAH, and the FACT-ES Trial Outcome Index (TOI) using "a little better" or "a little worse" responses on the patient-reported global rating of change in joint pain and joint stiffness.
- To assess whether patients receiving omega-3-fatty acid compared to placebo have an improved lipid profile as measured by triglycerides, HDL, and LDL.
- To assess the toxicity of omega-3-fatty acid compared to placebo in this setting.
- To assess whether there is a difference in serum-free and total estradiol levels before and after treatment with omega-3-fatty acid compared to placebo.
- To explore whether CYP19A1 genotype correlates with severity of joint symptoms or predicts response to omega-3-fatty acid. (exploratory)
- To explore changes in hormonal and inflammatory serum biomarkers, such as IL6, TNF-α, and CRP.
- To assess whether there is a relationship between change in serum docosahexaenoic acid (DHA) and EPA and resolution of joint symptoms.
- To establish a cohort of patients (placebo group) to better characterize the natural history of the syndrome.
OUTLINE: This is a multicenter study. Patients are stratified according to prior osteoarthritis (yes vs no) and prior taxane use (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample collection at baseline and at 12 and 24 weeks for biomarker and DNA analysis.
Patients complete the Brief Pain Inventory Short Form (BPI-SF), the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index, the Modified-Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH), the FACT-ES Trial Outcome Index, and the Omega-3-fatty acid Dietary Intake questionnaires at baseline and at 6, 12, and 24 weeks.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I | Experimental | Dietary Supplement: omega-3 fatty acidPatients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity. |
| Arm II | Placebo comparator | Other: placeboPatients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity. |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| omega-3 fatty acidGiven orally | Dietary supplement | Arm I |
| placeboGiven orally | Other | Arm II |
Primary outcome
Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score
Time frame: 12 weeks post-registration
Linear regression model-adjusted week 12 mean score by treatment group. Purpose: To assess the severity of pain Population: Patients with pain from chronic diseases or conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain Responsiveness: Responds to both behavioral and pharmacological pain interventions Method: Self-report or interview Scoring: Higher scores indicate more pain Range: 0-10
4 secondary outcomes
Number of Patients With Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug
Time frame: Up to 25 weeks
Week 12 Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score
Time frame: 12 weeks post-registration
Week 12 Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH) Score
Time frame: 12 weeks post-registration
Week 12 Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Score
Time frame: 12 weeks post-registration
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 25940724Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. J Clin Oncol. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4.
- Individual participant dataSharing planned: No
Related trials for Arthralgia
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Not yet recruiting
Geriatric Oncology Assessment and Coping Skills Training for Older Women on Aromatase Inhibitor Therapy
Breast Cancer, Hormone Receptor Positive, Aromatase Inhibitor-Associated Arthralgia
Recruiting
Hybrid mHealth and Telerehabilitation vs Conventional Physiotherapy for Subacromial Pain Syndrome
Subacromial Pain Syndrome
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
RecruitingPhase 2
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
Estrogen Receptor-Positive Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dawn Hershman, MD study chair
Herbert Irving Comprehensive Cancer Center
Laurence H. Baker, DO, FACOI principal investigator
University of Michigan Rogel Cancer Center
292 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing omega-3 fatty acid in people with Arthralgia and Breast Cancer, run by SWOG Cancer Research Network at 292 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 292 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score (time frame: 12 weeks post-registration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01385137, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2017.